MA54910A - Sels de pyridine et procédé - Google Patents

Sels de pyridine et procédé

Info

Publication number
MA54910A
MA54910A MA054910A MA54910A MA54910A MA 54910 A MA54910 A MA 54910A MA 054910 A MA054910 A MA 054910A MA 54910 A MA54910 A MA 54910A MA 54910 A MA54910 A MA 54910A
Authority
MA
Morocco
Prior art keywords
pyridine salts
pyridine
salts
Prior art date
Application number
MA054910A
Other languages
English (en)
Inventor
Hiroaki Inagaki
Hideaki Kageji
Yasuyuki Kaneta
Kiyoshi Nakayama
Hidenori Namiki
Yoshihiro Shibata
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MA54910A publication Critical patent/MA54910A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
MA054910A 2016-09-29 2017-09-28 Sels de pyridine et procédé MA54910A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016191725A JP2018052878A (ja) 2016-09-29 2016-09-29 ピリジン化合物

Publications (1)

Publication Number Publication Date
MA54910A true MA54910A (fr) 2022-04-13

Family

ID=60020249

Family Applications (2)

Application Number Title Priority Date Filing Date
MA46337A MA46337B1 (fr) 2016-09-29 2017-09-28 Composé de pyridine
MA054910A MA54910A (fr) 2016-09-29 2017-09-28 Sels de pyridine et procédé

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA46337A MA46337B1 (fr) 2016-09-29 2017-09-28 Composé de pyridine

Country Status (33)

Country Link
US (2) US10851092B2 (fr)
EP (2) EP3519398B1 (fr)
JP (2) JP2018052878A (fr)
KR (1) KR102520543B1 (fr)
CN (2) CN113788824A (fr)
AU (2) AU2017335242C1 (fr)
BR (1) BR112019006047A2 (fr)
CA (1) CA3035860A1 (fr)
CL (1) CL2019000844A1 (fr)
CO (1) CO2019004034A2 (fr)
CY (1) CY1123988T1 (fr)
DK (1) DK3519398T3 (fr)
EA (1) EA037103B1 (fr)
EC (1) ECSP19030134A (fr)
ES (1) ES2868748T3 (fr)
HR (1) HRP20210447T1 (fr)
HU (1) HUE054824T2 (fr)
IL (1) IL265630B (fr)
LT (1) LT3519398T (fr)
MA (2) MA46337B1 (fr)
MD (1) MD3519398T2 (fr)
MX (1) MX2019003747A (fr)
PE (1) PE20190805A1 (fr)
PH (1) PH12019500480A1 (fr)
PL (1) PL3519398T3 (fr)
PT (1) PT3519398T (fr)
RS (1) RS61640B1 (fr)
SG (1) SG11201901937WA (fr)
SI (1) SI3519398T1 (fr)
SM (1) SMT202100315T1 (fr)
UA (1) UA123964C2 (fr)
WO (1) WO2018060714A1 (fr)
ZA (1) ZA201902232B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3371171T1 (sl) 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
PE20210096A1 (es) 2018-04-03 2021-01-12 Blueprint Medicines Corp Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
JP7642556B2 (ja) * 2019-11-18 2025-03-10 中外製薬株式会社 併用医薬
CN113121524B (zh) 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
WO2021164741A1 (fr) * 2020-02-20 2021-08-26 南京明德新药研发有限公司 Composé de bisamide de phényle
US12565481B2 (en) 2020-02-20 2026-03-03 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory 6,7-dimethoxy-3-(pyridin-2-yl)quinoline compounds for inhibiting RET
EP4157829A1 (fr) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Formes solide de pralsetinib
WO2022238706A1 (fr) 2021-05-14 2022-11-17 Bp Asset Viii, Inc. Inhibiteur de ret pour le traitement du cancer médullaire de la thyroïde à altération de ret ou du cancer du poumon non à petites cellules à altération de ret
MX2024004848A (es) 2021-10-22 2024-07-15 Univ Houston System Metodos y composiciones para el tratamiento de lesiones inflamatorias cronicas, metaplasias, displasia y canceres de tejidos epiteliales.
CN115090331B (zh) * 2022-07-21 2023-05-16 扬州大学 超分子手性催化剂、其制备方法及其催化d-a反应的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
WO2005023761A2 (fr) 2003-09-11 2005-03-17 Kemia, Inc. Inhibiteurs des cytokines
WO2007099323A2 (fr) 2006-03-02 2007-09-07 Astrazeneca Ab Dérivés de la quinoline
EP1994023A1 (fr) 2006-03-02 2008-11-26 AstraZeneca AB Dérivés de la quinazoline
WO2007113565A1 (fr) 2006-04-06 2007-10-11 Astrazeneca Ab Dérivés de la naphtyridine comme agents anti-cancéreux
WO2007113548A1 (fr) 2006-04-06 2007-10-11 Astrazeneca Ab Dérivés de naphtyridine
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
SG173884A1 (en) * 2009-02-27 2011-10-28 Teijin Pharma Ltd Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst
MX2012001974A (es) 2009-08-19 2012-04-11 Ambit Biosciences Corp Compuestos de biarilo y metodos de uso de los mismos.
EP3103452A1 (fr) 2009-08-25 2016-12-14 Abraxis BioScience, LLC Thérapie de combinaison avec des compositions de nanoparticules de taxane et inhibiteurs hedgehog
CN102946881A (zh) 2010-04-23 2013-02-27 奇尼塔公司 抗病毒化合物
JP6097998B2 (ja) 2010-12-16 2017-03-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のビアリールアミドインヒビター
US9212209B2 (en) 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
SMT201700152T1 (it) * 2013-03-15 2017-05-08 Glaxosmithkline Ip Dev Ltd Derivati piridinici come inibitori della chinasi riarrangiata durante la trasfezione (ret)
KR20160055170A (ko) 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 바이아릴 아세트아미드 화합물 및 이의 사용 방법
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
US9783522B2 (en) * 2014-04-24 2017-10-10 Mitsubishi Tanabe Pharma Corporation 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof
WO2016038552A1 (fr) * 2014-09-10 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Dérivés de pyridone à titre d'inhibiteurs de la kinase réarrangée au cours de la transfection (ret)
WO2016037578A1 (fr) * 2014-09-10 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Nouveaux composés utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret)
US10626094B2 (en) 2014-10-14 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
CN104844589B (zh) 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
WO2016127074A1 (fr) * 2015-02-06 2016-08-11 Blueprint Medicines Corporation Utilisation de dérivés 2-(pyridine-3-yl)-pyrimidine en tant qu'inhibiteurs de ret
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物

Also Published As

Publication number Publication date
ZA201902232B (en) 2022-12-21
PT3519398T (pt) 2021-03-24
US20210163464A1 (en) 2021-06-03
KR20190086442A (ko) 2019-07-22
WO2018060714A1 (fr) 2018-04-05
DK3519398T3 (da) 2021-03-29
CL2019000844A1 (es) 2019-06-07
HRP20210447T1 (hr) 2021-07-23
US20200039974A1 (en) 2020-02-06
HUE054824T2 (hu) 2021-10-28
IL265630A (en) 2019-05-30
EA201990833A1 (ru) 2019-10-31
PE20190805A1 (es) 2019-06-10
MA46337A (fr) 2019-08-07
CN110036007A (zh) 2019-07-19
LT3519398T (lt) 2021-05-10
AU2017335242B2 (en) 2021-08-19
ECSP19030134A (es) 2019-08-30
MA46337B1 (fr) 2021-04-30
CN113788824A (zh) 2021-12-14
PH12019500480A1 (en) 2019-08-05
RS61640B1 (sr) 2021-04-29
KR102520543B1 (ko) 2023-04-10
EA037103B1 (ru) 2021-02-05
AU2017335242A1 (en) 2019-05-02
AU2021261899A1 (en) 2021-12-02
BR112019006047A2 (pt) 2019-06-25
ES2868748T3 (es) 2021-10-21
MX2019003747A (es) 2019-09-19
PL3519398T3 (pl) 2021-06-28
MD3519398T2 (ro) 2021-05-31
EP3519398B1 (fr) 2021-02-24
AU2017335242C1 (en) 2021-12-09
JP2019534871A (ja) 2019-12-05
SMT202100315T1 (it) 2021-07-12
IL265630B (en) 2021-10-31
EP3519398A1 (fr) 2019-08-07
SI3519398T1 (sl) 2021-07-30
EP3828178A1 (fr) 2021-06-02
JP2018052878A (ja) 2018-04-05
CO2019004034A2 (es) 2019-07-10
US10851092B2 (en) 2020-12-01
CN110036007B (zh) 2021-10-15
JP7098609B2 (ja) 2022-07-11
CA3035860A1 (fr) 2018-04-05
SG11201901937WA (en) 2019-04-29
UA123964C2 (uk) 2021-06-30
CY1123988T1 (el) 2022-05-27

Similar Documents

Publication Publication Date Title
MA54910A (fr) Sels de pyridine et procédé
MA56137A (fr) Sels de valbénazine et leurs polymorphes
EP3377307A4 (fr) Composition structurale et procédé
EP3609241A4 (fr) Procédé de réveil de site et site
EP3486039A4 (fr) Robot et procédé de commande de robot
EP3287793A4 (fr) Auto-analyseur et procédé
EP3536412A4 (fr) Laminoir et procédé de réglage de laminoir
EP3430189A4 (fr) Machine à touffeter et procédé de touffetage
EP3470880A4 (fr) Système de télémétrie et procédé de télémétrie
MA46973A (fr) Polymorphes de sépiaptérine et leurs sels
EP3325990A4 (fr) Système et procédé de gradiomètre
EP3323516A4 (fr) Procédé de revêtement et dispositif de revêtement
EP3447730A4 (fr) Procédé de reconstruction tridimensionnelle
EP3313033A4 (fr) Dispositif et procédé
EP3531575A4 (fr) Procédé et dispositif de formation de faisceau
EP3525361A4 (fr) Procédé et dispositif de formation de faisceau
EP3313615A4 (fr) Article abrasif et procédé de formation associé
EP3483616A4 (fr) Circuit et procédé de détection
EP3352823A4 (fr) Sels cristallins de naloxone et de naltrexone
EP3393818A4 (fr) Étiquette automasquante et procédé
EP3396021A4 (fr) Structure de connexion par brasure et procédé de formation de film
EP3361808A4 (fr) Dispositif et procédé
EP3369044A4 (fr) Étiquette inviolable et procédé associé
EP3470546A4 (fr) Procédé de formation de film
EP3331415A4 (fr) Générateur de vapeur et procédé de commande de générateur de vapeur